<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646371</url>
  </required_header>
  <id_info>
    <org_study_id>SF2A-2B</org_study_id>
    <nct_id>NCT02646371</nct_id>
  </id_info>
  <brief_title>Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a</brief_title>
  <official_title>Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LimmaTech Biologics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LimmaTech Biologics AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proof of concept challenge study, the bioconjugate candidate vaccine Flexyn2a will be&#xD;
      tested for its ability to induce an immune response that protects healthy adult volunteers&#xD;
      from infection with a wild-type Shigella flexneri 2a strain compared to subjects receiving&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flexyn2a is a bioconjugate candidate vaccine that is able to induce an humoral immune&#xD;
      response specific for the 2a-antigen of Shigella flexneri 2a bacteria. Healthy adult&#xD;
      volunteers naïve for Shigella flexneri 2a infections at screening will receive two&#xD;
      administrations of 10 micrograms Flexyn2a or placebo 4 weeks apart. Four weeks after the&#xD;
      second vaccination, each subject will be challenged with 1500 cfu of the virulent Shigella&#xD;
      flexneri 2a strain 2457T. In order to assess the ability of Flexyn2a to protect against&#xD;
      infection with this strain, the attack rate of shigellosis in the group vaccinated with&#xD;
      Flexyn2a will be compared to the group of the subjects who received placebo injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attack Rate of Shigellosis in Vaccinated Subjects.</measure>
    <time_frame>Between Day 56 and Day 64</time_frame>
    <description>The attack rate of shigellosis after challenge in vaccine group versus in placebo group was analyzed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Shigellosis</condition>
  <arm_group>
    <arm_group_label>Flexyn2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 doses of TBS solution will be injected intramuscularly 4 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flexyn2a</intervention_name>
    <description>2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart</description>
    <arm_group_label>Flexyn2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 doses of TBS solution will be injected intramuscularly 4 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 18-50 years (inclusive)&#xD;
&#xD;
          -  Good health, without clinically significant medical history or physical examination&#xD;
             findings.&#xD;
&#xD;
          -  Negative serum pregnancy test at screening, and negative urine before each vaccination&#xD;
             and before challenge for female subjects of childbearing potential.&#xD;
&#xD;
          -  Females of childbearing potential must agree to avoid pregnancy by use of effective&#xD;
             contraception. Abstinence is not acceptable as effective contraception. Female&#xD;
             subjects unable to bear children must have this documented (e.g. tubal ligation or&#xD;
             hysterectomy).&#xD;
&#xD;
          -  Willingness to participate in the study after all aspects of the protocol have been&#xD;
             explained and written informed consent obtained.&#xD;
&#xD;
          -  Completion of a training session and demonstrated comprehension of the protocol&#xD;
             procedures, knowledge of Shigella-associated illness, and a passing score of 70% or&#xD;
             better on a written examination.&#xD;
&#xD;
          -  Availability for the study duration, including all planned follow-up visits.&#xD;
&#xD;
          -  Willingness to refrain from participating in other studies of investigational products&#xD;
             until completion of the last study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women currently nursing.&#xD;
&#xD;
          -  Presence of a significant medical or psychiatric condition which in the opinion of the&#xD;
             investigator precludes participation in the study.&#xD;
&#xD;
          -  Clinically significant abnormalities in screening hematology or serum chemistry as&#xD;
             determined by PI or PI in consultation with the research monitor and sponsor.&#xD;
&#xD;
          -  Presence in the serum of HIV antibody, HBs-Ag, or HCV antibody (if confirmed positive&#xD;
             by HepC confirmatory test, i.e. RIBA, PCR)&#xD;
&#xD;
          -  Evidence of IgA deficiency (serum IgA &lt; 7 mg/dl or limit of detection of assay).&#xD;
&#xD;
          -  Evidence of current excessive alcohol consumption or drug dependence.&#xD;
&#xD;
          -  Evidence of impaired immune function.&#xD;
&#xD;
          -  BMI &lt;19 and ≥35&#xD;
&#xD;
          -  Recent vaccination or receipt of an investigational product (within 30 days before&#xD;
             vaccination and until last study visit).&#xD;
&#xD;
          -  Personal history of an inflammatory arthritis.&#xD;
&#xD;
          -  Positive blood test for HLA-B27.&#xD;
&#xD;
          -  Personal history of irritable bowel syndrome as defined by Rome III criteria.&#xD;
&#xD;
          -  Treatment with immunoglobulins or blood products within 3 months from first candidate&#xD;
             vaccine injection.&#xD;
&#xD;
          -  Regularly abnormal stool pattern (fewer than 3 per week or more than 3 per day) or&#xD;
             loose or liquid stools&#xD;
&#xD;
          -  Regular use of laxatives, antacids, or other agents to lower stomach acidity.&#xD;
&#xD;
          -  Use of any medication known to affect the immune function (e.g., systemic steroids)&#xD;
             within 30 days preceding the first vaccination or planned use during the entire study&#xD;
             period.&#xD;
&#xD;
          -  Known allergy to any of the following antibiotics: ciprofloxacin,&#xD;
             trimethoprim-sulfamethoxazole or penicillin.&#xD;
&#xD;
          -  Symptoms consistent with Traveler's Diarrhea concurrent with travel to countries where&#xD;
             Shigella infection is endemic (most of the developing world) within two years prior to&#xD;
             dosing, OR planned travel to endemic countries during the length of the study.&#xD;
&#xD;
          -  Vaccination for or ingestion of Shigella within 3 years prior to vaccination.&#xD;
&#xD;
          -  Use of antibiotics during the 7 days before vaccination and challenge&#xD;
&#xD;
          -  Use of proton pump inhibitors, H2 blockers or antacids within 48 hours prior to&#xD;
             challenge.&#xD;
&#xD;
          -  Serum IgG titer to Shigella flexneri 2a LPS ≥ 2500&#xD;
&#xD;
          -  Current occupation involving handling of Shigella bacteria&#xD;
&#xD;
          -  History of allergy to any vaccine or to soy&#xD;
&#xD;
          -  Any other criteria which, in the investigator's opinion, would compromise the ability&#xD;
             of the subject to participate in the study, the safety of the study, or the results of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kawsar R Talaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Martin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LimmaTech Biologics AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bloomberg School of Public Health, CIR</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <results_first_submitted>August 26, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <disposition_first_submitted>February 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 22, 2018</disposition_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flexyn2a - Vaccination</title>
          <description>2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart&#xD;
Flexyn2a: 2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Vaccination</title>
          <description>2 doses of TBS solution will be injected intramuscularly 4 weeks apart&#xD;
Placebo: 2 doses of TBS solution will be injected intramuscularly 4 weeks apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flexyn2a - Vaccination</title>
          <description>2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart&#xD;
Flexyn2a: 2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Vaccination</title>
          <description>2 doses of TBS solution will be injected intramuscularly 4 weeks apart&#xD;
Placebo: 2 doses of TBS solution will be injected intramuscularly 4 weeks apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" lower_limit="23.5" upper_limit="49.8"/>
                    <measurement group_id="B2" value="34.4" lower_limit="22.3" upper_limit="50.3"/>
                    <measurement group_id="B3" value="35.5" lower_limit="22.3" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Attack Rate of Shigellosis in Vaccinated Subjects.</title>
        <description>The attack rate of shigellosis after challenge in vaccine group versus in placebo group was analyzed.</description>
        <time_frame>Between Day 56 and Day 64</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flexyn2a</title>
            <description>The Flexyn2a treatment arm that was challenged.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The control (Placebo) treatment arm that was challenged.</description>
          </group>
        </group_list>
        <measure>
          <title>Attack Rate of Shigellosis in Vaccinated Subjects.</title>
          <description>The attack rate of shigellosis after challenge in vaccine group versus in placebo group was analyzed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flexyn2a - Vaccination</title>
          <description>In the Flexyn2a treatment arm - 34 subjects received the first Flexyn2a vaccine and 34 subjects received the second Flexyn2a vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Vaccination</title>
          <description>In the control treatment (Placebo) arm - 34 subjects received the first Placebo vaccine and 30 subjects received the second Placebo vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Blood and lymphatic)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Cardiac disorders)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Eye disorders)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Gastrointestinal disorders)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (General disorders and administration site conditions)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Infections and infestations)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Injury, poisoning and procedural complications)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Investigations)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Metabolism and nutrition disorders)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Musculoskeletal and connective tissue disorders)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Respiratory, thoracic and mediastinal disorders)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited (Skin and subcutaneous tissue disorders)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>LimmaTech Biologics AG</organization>
      <phone>+41 44 733 8585</phone>
      <email>info@lmtbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

